Cargando…

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholestero...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Xiaoming, Al Rifai, Mahmoud, Saeed, Anum, Ballantyne, Christie M, Virani, Salim S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309324/
https://www.ncbi.nlm.nih.gov/pubmed/35898405
http://dx.doi.org/10.2147/VHRM.S275739
_version_ 1784753135081750528
author Jia, Xiaoming
Al Rifai, Mahmoud
Saeed, Anum
Ballantyne, Christie M
Virani, Salim S
author_facet Jia, Xiaoming
Al Rifai, Mahmoud
Saeed, Anum
Ballantyne, Christie M
Virani, Salim S
author_sort Jia, Xiaoming
collection PubMed
description Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.
format Online
Article
Text
id pubmed-9309324
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-93093242022-07-26 PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance Jia, Xiaoming Al Rifai, Mahmoud Saeed, Anum Ballantyne, Christie M Virani, Salim S Vasc Health Risk Manag Review Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development. Dove 2022-07-20 /pmc/articles/PMC9309324/ /pubmed/35898405 http://dx.doi.org/10.2147/VHRM.S275739 Text en © 2022 Jia et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Jia, Xiaoming
Al Rifai, Mahmoud
Saeed, Anum
Ballantyne, Christie M
Virani, Salim S
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
title PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
title_full PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
title_fullStr PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
title_full_unstemmed PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
title_short PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance
title_sort pcsk9 inhibitors in the management of cardiovascular risk: a practical guidance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309324/
https://www.ncbi.nlm.nih.gov/pubmed/35898405
http://dx.doi.org/10.2147/VHRM.S275739
work_keys_str_mv AT jiaxiaoming pcsk9inhibitorsinthemanagementofcardiovascularriskapracticalguidance
AT alrifaimahmoud pcsk9inhibitorsinthemanagementofcardiovascularriskapracticalguidance
AT saeedanum pcsk9inhibitorsinthemanagementofcardiovascularriskapracticalguidance
AT ballantynechristiem pcsk9inhibitorsinthemanagementofcardiovascularriskapracticalguidance
AT viranisalims pcsk9inhibitorsinthemanagementofcardiovascularriskapracticalguidance